Department of Neurology, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA.
Hum Mol Genet. 2011 Sep 1;20(17):3331-45. doi: 10.1093/hmg/ddr239. Epub 2011 May 30.
Calpain 3 (CAPN3) is a muscle-specific, calcium-dependent proteinase that is mutated in Limb Girdle Muscle Dystrophy type 2A. Most pathogenic missense mutations in LGMD2A affect CAPN3's proteolytic activity; however, two mutations, D705G and R448H, retain activity but nevertheless cause muscular dystrophy. Previously, we showed that D705G and R448H mutations reduce CAPN3s ability to bind to titin in vitro. In this investigation, we tested the consequence of loss of titin binding in vivo and examined whether this loss can be an underlying pathogenic mechanism in LGMD2A. To address this question, we created transgenic mice that express R448H or D705G in muscles, on wild-type (WT) CAPN3 or knock-out background. Both mutants were readily expressed in insect cells, but when D705G was expressed in skeletal muscle, it was not stable enough to study. Moreover, the D705G mutation had a dominant negative effect on endogenous CAPN3 when expressed on a WT background. The R448H protein was stably expressed in muscles; however, it was more rapidly degraded in muscle extracts compared with WT CAPN3. Increased degradation of R448H was due to non-cysteine, cellular proteases acting on the autolytic sites of CAPN3, rather than autolysis. Fractionation experiments revealed a significant decrease of R448H from the myofibrillar fraction, likely due to the mutant's inability to bind titin. Our data suggest that R448H and D705G mutations affect both CAPN3s anchorage to titin and its stability. These studies reveal a novel mechanism by which mutations that spare enzymatic activity can still lead to calpainopathy.
钙蛋白酶 3(CAPN3)是一种肌肉特异性、钙依赖性蛋白水解酶,在 2A 型肢带型肌肉营养不良症中发生突变。LGMD2A 中大多数致病性错义突变影响 CAPN3 的蛋白水解活性;然而,两种突变,D705G 和 R448H,保留了活性,但仍导致肌肉营养不良。以前,我们表明 D705G 和 R448H 突变降低了 CAPN3 在体外与肌联蛋白结合的能力。在这项研究中,我们测试了肌联蛋白结合缺失的体内后果,并研究了这种缺失是否可以成为 LGMD2A 的潜在致病机制。为了解决这个问题,我们创建了在肌肉中表达 R448H 或 D705G 的转基因小鼠,在野生型(WT)CAPN3 或敲除背景下。两种突变体都可以在昆虫细胞中容易地表达,但当 D705G 在骨骼肌中表达时,它不够稳定,无法进行研究。此外,当在 WT 背景下表达时,D705G 突变对内源性 CAPN3 具有显性负效应。R448H 蛋白在肌肉中稳定表达;然而,与 WT CAPN3 相比,它在肌肉提取物中的降解速度更快。R448H 降解的增加是由于非半胱氨酸、细胞蛋白酶作用于 CAPN3 的自溶位点,而不是自溶。分馏实验表明,R448H 从肌原纤维部分显著减少,可能是由于突变体无法与肌联蛋白结合。我们的数据表明,R448H 和 D705G 突变既影响 CAPN3 与肌联蛋白的锚定,又影响其稳定性。这些研究揭示了一种新的机制,即保留酶活性的突变仍可导致钙蛋白酶病。